Renata PLC (DSE:RENATA)

Market Cap	47.16B
Revenue (ttm)	44.03B
Net Income (ttm)	2.37B
Shares Out	114.70M
EPS (ttm)	20.64
PE Ratio	19.92
Forward PE	13.24
Dividend	5.50 (1.33%)
Ex-Dividend Date	Nov 18, 2025

Volume	30,955
Average Volume	29,376
Open	413.20
Previous Close	413.70
Day's Range	411.00 - 415.00
52-Week Range	372.00 - 597.50
Beta	-0.14
RSI	67.97
Earnings Date	Jan 29, 2026

About Renata

Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxicity in pedia...

• Industry: Pharmaceutical Preparations
• Founded: 1972
• Employees: 8,366
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: RENATA

Financial Performance

In 2025, Renata's revenue was 42.89 billion, an increase of 13.74% compared to the previous year's 37.71 billion. Earnings were 2.22 billion, a decrease of -38.58%.